苏格兰癌症与心力衰竭的患病率、发病率及预后研究
结果显示扩大心衰定义人群的癌症发病率略高,同时患癌症与心衰者预后最差。癌症与心血管死亡比例相近,仅约20%患者在家中死亡。
要点
- 心衰扩大定义人群的癌症发病率略高于无心衰者,但不同癌种风险存在差异。
- 同时患有癌症与心衰扩大定义者年死亡率最高,癌症与心血管死亡占比相近。
- 仅约20%的患者在家中死亡,提示终末期照护地点值得关注。
核心结论
- 心衰扩大定义人群的癌症总体风险略高,但可能因癌症类型而异。
- 同时患癌症与心衰扩大定义者预后差,癌症与心血管疾病所致死亡比例相近。
研究设计与样本
- 基于苏格兰一个地区的健康记录开展回顾性队列研究。
- 纳入50岁以上人群,按心衰、袢利尿剂使用和癌症状态进行分类。
主要发现
- 无心衰且无癌症者年死亡率低于3%,多数死亡为心血管原因。
- 有癌症但无心衰扩大定义者中,女性年死亡率为6.3%,男性为9.0%,多数死于癌症。
临床怎么用
- 对心衰扩大定义人群应关注癌症风险,但需结合具体癌症类型评估。
- 癌症与心衰扩大定义并存者的管理需兼顾心血管与肿瘤两方面风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Many patients with cancer develop heart failure (HF), and many patients with HF develop cancer. Inter-relationships between their natural histories are rarely reported. METHODS: Health records were obtained for a Scottish region. People aged >50 years were classified by the presence or absence of HF, loop diuretics (a pharmacological marker of congestion), and cancer. Incident cancer, mortality, and cause of death were recorded. RESULTS: Of 317 178 people aged >50 years, 11 268 (3.6%) had HF of whom 6276 were prescribed loop diuretics; a further 19 044 (6.0%) received loop diuretics. Thus, 30 312 (9.6%) people met an expanded definition of heart failure (HFexp). Annual cancer incidence was slightly higher for those with HFexp (incidence rate ratio 1.10; P < .001), varying amongst cancer types. For people with neither cancer nor HFexp, mortality was <3% annually; most deaths were cardiovascular. For those with cancer but not HFexp, annual mortality was 6.3% for women and 9.0% for men; most died of cancer. For those with HFexp but not cancer, annual mortality ranged from 6.6% to 18.4% depending on sex and HFexp criteria applied; most deaths were cardiovascular. For those with both cancer and HFexp, annual mortality ranged from 14.5% to 28.4%; cardiovascular and cancer mortality rates were similar. Few patients died at home (∼20%). CONCLUSIONS: Patients with HFexp have a slightly higher risk of cancer overall, but this may vary according to cancer type. Patients with both cancer and HFexp have a poor prognosis with a similar proportion of deaths attributed to cancer and cardiovascular disease.
引用
- Iaconelli, Morsy, Friday, et al. Cancer and heart failure: prevalence, incidence, and prognosis in Scotland. Eur Heart J. 2026. PMID: 42068332. doi:10.1093/eurheartj/ehag120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。